Guidant Corp

Guidant — Merger or Acquisition (September 2002)

82 slides from Guidant's merger presentation, Sep 18, 2002

  1. Slide 1: Ronald W. Dollens, President & Chief Executive Officer

    Ronald W. Dollens President & Chief Executive Officer

  2. Slide 2: Value Creation Through Sustainable Growth

    Value Creation Through Sustainable Growth Operational Capability Competitive Structure Growth Opportunities Health Policy

  3. Slide 3: A Unique Position

    A Unique Position Implantable Defibrillators Market Development Heart Failure MADIT II Drug Eluting Stents Product Development Multiple Programs Basis of Competition Emerging Therapies Leverage

  4. Slide 4: Key observations

    Key observations Unique Market Position Acquisition of Cook Group should bring Legal, Operational and Economic benefits Cook Group - attractive growth and profitability profile Structure provides Guidant Shareholders key contingencies Minimum share prices of $40 and $55 in two phases Maximum number

  5. Slide 5: Drug Eluting Stent technology drives market growth

    Drug Eluting Stent technology drives market growth Source: Guidant estimates $0.1 $0.2 $0.7 $1.1 $1.4 $1.5 $1.3 $1.2 $0.1 $1.4 $2.3 $0.8 $4.5 1994 1997 2001 2004E '01-'04 CAGR $3.1 $4.3 $7.6 $1.6 Vascular Intervention Market Angioplasty/ guidewires Other Bare metal stents Drug eluting stents 21% $ b

  6. Slide 6: Major cardiovascular technology market growth drivers

    Major cardiovascular technology market growth drivers 1 Includes impact of CHF Source: Guidant estimates $3.0 $3.7 $1.9 $3.5 $0.4 $0.6 2001 2004E CAGR $5.3 $7.8 Cardiac Rhythm Management Market Pacemakers (Brady)1 ICDs (Tachy)1 Ablation 22% 14% $ billions Heart Failure MADIT II

  7. Slide 7: For Guidant, it's about...

    For Guidant, it's about: Drug Eluting Stents Heart Failure MADIT II Financial Performance

  8. Slide 8: Guidant: Positioned to capture leadership in DES

    + + Internal R&D productivity (delivery systems and stents) MULTI-LINK ZETATM2 MULTI-LINK, DUET, TRISTAR, TETRA, PENTA Rapid exchange platform Over-the-wire platforms Developed lesion specific stents PIXELTM, ULTRATM, FRONTIERTM3 Sales force excellence Stent market share leadership for 18 of the las

  9. Slide 9: Cook Group Acquisition Contingencies

    Cook Group Acquisition Contingencies Clinical Results reduction in TVF by 50% MI and death rates < control Clear Rights to Sell Cook Group Transaction Adds Clarity Affiliate of Licensee Declaratory Judgment Action Filed

  10. Slide 10: Cook v. BSC Litigation Update

    Cook v. BSC Litigation Update Strong public interest in continuing potentially life saving product (public health considerations) Federal law [271(e)(1)] exempts from patent infringement the collection and use of clinical data for purposes of obtaining regulatory approval Balancing of potential harm

  11. Slide 11: Implantable Defibrillator WW Market

    Implantable Defibrillator WW Market Q1 '99 Q2 '99 Q3 '99 Q4 '99 Q1 '00 Q2 '00 Q3 '00 Q4 '00 Q1 '01 Q2 '01 Q3 '01 Q4 '01 Q1 '02 Q2 '02 Guidant 110 115 111 108 130 150 138 131 138 146 140 148 156 205 Market less Guidant 164 161 169 173 202 181 193 196 219 213 222 244 309 300 $ millions Guidant Revenue

  12. Slide 12: Guidant Financial Performance

    Guidant Financial Performance* Revenue $807 +23% $1,517 +14% Gross Profit 599 1,137 Income Before Taxes 221 415 Net Income 163 +42% 307 +27% % of Sales 20% 20% Earnings Per Share $.53 $1.00 * As adjusted Q3 Guidance Sales: $800 - $825 EPS $.52 - $.55 Q2 '02 (vs Q1'01) FH '02 (vs FH'01)

  13. Slide 13: Enhancing Shareholder Value

    Enhancing Shareholder Value Guidant uniquely positioned to participate in / lead exceptional growth markets Heart Failure MADIT II (expanded prophylactic use of Implantable Defibrillators) Drug Eluting Stents Cook Group deal offers additional clarity to unleash drug eluting stent opportunity Intelle

  14. Slide 14: Keith E. Brauer, Vice President & Chief Financial Officer

    Keith E. Brauer Vice President & Chief Financial Officer

  15. Slide 15: Q3 2002 guidance

    $800M - $825M sales 21% - 25% sales growth v. Q3 '01 EPS: $.52 - $.55 30% - 38% EPS growth v. Q3 '01 Q3 '02

  16. Slide 16: 2002 guidance

    $3.0B - $3.2B sales 14% - 17% sales growth v. 2001 EPS: $2.00 - $2.06 20% - 24% EPS growth v. 2001 2002 *All EPS as adjusted

  17. Slide 17: 2003 guidance

    Sales $4B+ (includes Cook base business) EPS: $2.15 - $2.21 2003 *All EPS as adjusted

  18. Slide 18: 2003 Scenario Analysis

    Cypher launch date - 12/02 Achieve launch date - 9/03 Achieve market share Sept - Dec = 38% DES market adoption 65% for 2003 BMS market unit erosion but more procedures and higher utilization BMS ASP - down 20% Cook closing date - 1/3/03 Guidant Assumptions 2003 EPS: $2.15 - $2.21 Heart Failure and

  19. Slide 19: 2004 outlook

    2004 Sales growth in the high 20's EPS growth exceeds sales growth

  20. Slide 20: Financial Flexibility: 2000 - 2004

    2000 2001 2002E 2003E 2004E Net Debt -640 -313 514 1123 2196 Financial Flexibility: 2000 - 2004 \

  21. Slide 21: Long Term Goal

    Long Term Our Goal: To continue as a high margin, innovative business that averages sustainable and predictable sales and earnings growth in the mid teens over any five year period.

  22. Slide 22: Long Term Performance: 1994 - 2002

    1994 1995 1996 1997 1998 1999 2000 2001 2002 Sales** 862.4 931.3 1049.7 1337.6 1913.1 2352.3 2548.7 2707.6 3149.6 Net Income** 68.3 91.8 120.3 175 337.5 411 491.5 509.2 646.7 *2002 Guidance **As adjusted 17.6% CAGR 32.4% CAGR Long Term Performance: 1994 - 2002*

  23. Slide 23: Peer Comparison

    MDT BSX STJ GDT East 25.4 24.7 22.7 16.4 Note: Stock price effective as of 9/13/02; 2003 earnings based on First Call consensus Peer Comparison

  24. Slide 24: John Capek, Ph.D., President, Vascular Intervention

    John Capek, Ph.D. President, Vascular Intervention

  25. Slide 25: Latest developments in Vascular Intervention

    Latest developments in Vascular Intervention CE Mark for ACHIEVE granted August 30th US Stent Share momentum continues through 2002 Q3 QTD Average 48% Stent Share U.S. approval and launch of ZETA Launch rollout to be completed in 8 weeks Patient enrollment for the Deliver II clinical trial completed

  26. Slide 26: VI Market Opportunities

    VI Market Opportunities Leadership in Core Vascular Intervention Markets DES offers significant long-term growth Tremendous revenue upside Market CAGR (2002-2005) > 20% Continued patient growth Significant clinical benefit Increased penetration and patient volume due to migration of patients from CA

  27. Slide 27: Drug Eluting Stent Drives WW Vascular Market Growth

    1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Angioplasty 1455 1542 1496 1417 1393 1435 1398 1333 1286 1265 1255 1268 Bare Stent 94 507 873 1113 1717 1942 2021 1997 1972 1055 533 371 DES 0 0 0 0 0 0 0 0 108 2793 4555 5282 RT 0 0 0 0 0 0 7 80 115 105 83 60 EPD 0 0 0 0 0 0 0 24 78 152 19

  28. Slide 28: Guidant's Long Term Strategy

    Guidant's Long Term Strategy Sustain Global VI stent leadership Market leadership in DES with multiple platforms and drugs Superior deliverability platforms Continue to bring innovative products to market Cobalt Chrome Stent* Side Branch Access Stent** Embolic Protection Device** Invest in next gene

  29. Slide 29: Solid Market Leadership

    Solid Market Leadership

  30. Slide 30: US Revenue Shares 2002

    US Revenue Shares 2002 (1st half '02) Q2'02 GDT 0.39 MDT 0.13 JNJ 0.25 BSX 0.22 * Estimates based on competitive earnings releases by GDT market research. Guidant is over 50% larger then the next nearest competitor BSX GDT MDT JNJ

  31. Slide 31: Guidant VI is the US Market Leader

    Guidant VI is the US Market LEADER Stents BDC Cutting Ballon GW GC Atherectomy GDT 140.323 23.157 17.299 6.265 1.043 MDT 52.25 4.142 1.066 4.5 - BSX 25 24.75 19.8 9.658 10.3 13.8 JNJ 101.175 3.765 3.091 11 - Q2 2002 Est. Source: VI Market Intelligence 8/02 - Based on internal VI data and competitive

  32. Slide 32: Guidant continues to lead US Stent market

    Guidant continues to lead US Stent market 8/1/2001 9/1/2001 10/1/2001 11/1/2001 12/1/2001 1/1/2002 2/1/2002 3/1/2002 4/1/2002 5/1/2002 6/1/2002 7/1/2002 GDT 0.38 0.43 0.43 0.46 0.47 0.46 0.45 0.47 0.49 0.49 0.48 0.48 MDT 0.28 0.23 0.22 0.19 0.2 0.19 0.18 0.17 0.16 0.16 0.16 0.16 BSX 0.1 0.09 0.1 0.1

  33. Slide 33: Non U.S. Stent sales over 50% of VI Business

    Non U.S. Stent sales over 50% of VI Business Q3'01 Q4'01 Q1'02 Q2'02 Non U.S. Stent 155.397 169.493 165.812 181.818 % of Total Sales 155 169 166 182 U.S. Stent 135.058 162.202 156.319 153.707

  34. Slide 34: European Stent market leadership

    European Stent market leadership Q3 01 Q4 01 Q1 02 Q2 02 GDT 0.39 0.39 0.37 0.38 MDT 0.32 0.3 0.28 0.26 BSX 0.09 0.13 0.14 0.14 JNJ 0.2 0.18 0.21 0.22 BSX EXPRESS I Sept. 2001 BSX EXPRESS II May 2002 JNJ Cypher April 2002 GDT ZETA May 2002 Source: GDT VI Market Intelligence

  35. Slide 35: European stent sales maintain strong volume

    European stent sales maintain strong volume JNJ Cypher Q2'02 BSX Express II Q2'02

  36. Slide 36: Steady gains in Japanese Stent Market

    Steady gains in Japanese Stent Market Q3 01 Q4 01 Q1 02 Q2 02 July GDT 0.27 0.27 0.33 0.37 0.4 BSX 0.31 0.18 0.13 0.13 0.11 JNJ 0.01 0.34 0.33 0.32 0.29 MDT 0.37 0.15 0.14 0.14 0.15 Terumo 0.04 0.06 0.07 0.05 0.05 JNJ Velocity Sept. 2001 GDT Tristar Nov. 2001 Source: GDT VI Market Intelligence

  37. Slide 37: Radiation performance continues to improve

    Radiation performance continues to improve Galileo III* launch plan Launched OUS (Galileo 40/60), U.S. launch expected September 2002 New catheter and cartridge upgrade from previous system 194 signed contracts to date, greater than 1/3 leverage core business Contracts that leverage core VI business

  38. Slide 38: Breadth of Product Offerings: Platform Matters

    Breadth of Product Offerings "Platform Matters"

  39. Slide 39: Guidant Stent Strategy

    Guidant Stent Strategy Annual Product Iterations 6 platforms in the last 5 years Lesion Specific Designs to meet clinical needs Large Vessel Stent ..... ULTRA Small Vessel (SV) Stent ..... PIXEL Side Branch Access (SBA) Stent ..... FRONTIER* New Technologies to enhance performance QuicktrackTM ST ba

  40. Slide 40: Superior Deliverability

    Caution: Investigational Device. Limited by Federal (U.S.) law to investigational use only. Not available for sale. ** As compared to Velocity, S7, and Express * In-house tests demonstrate ML Zeta is more deliverable than the ML Penta(r). Data on file at Guidant. Superior Deliverability* Flexible st

  41. Slide 41: ZETA vs. BX Velocity

    ZETATM* vs. BX Velocity Photographs taken by and are on file at Guidant. Tests performed by and data on file at Guidant. Mean Distal STS = 0.638mm 3.0x18mm PENTA(tm) Mean Distal STS = 1.545mm 3.0x18mm BX Velocity Stent To Shoulder Distance Mean Distal STS = 0.634mm 3.0x18mm ZETA(tm)* * Caution: Inve

  42. Slide 42: ML ZETA Performance Testing

    ML ZETA* Performance Testing Blinded physician survey conducted to evaluate the performance of ZETA vs. ML PENTA JNJ BX Sonic Boston Scientific Express Medtronic S7 6 Physicians from Europe Germany, France, Sweden, Denmark, Italy Two Testing Models: Animal Model Synthetic Arterial Model (SAM) Penta

  43. Slide 43: Survey results support Superior Deliverability with the ZETA

    Survey results support Superior Deliverability with the ZETA* 1= significantly worse; 2= worse; 3= control; 4= better; 5= significantly better PENTA ZETA* Sonic Express S7 East 3 4.04 2.63 1.63 2.5 *Caution: Investigational Device. Limited by Federal (U.S.) law to investigational use only. Not avail

  44. Slide 44: MULTI-LINK VISION

    MULTI-LINK VISIONTM* Cobalt Chromium Alloy allows for low system profiles Based on MULTI-LINK(r) design with flexible links Thin struts (.0032") Better radiopacity than stainless steel VISIONTM Registry Enrollment completed in record time! - - Results to be reported at TCT Caution: Investigational D

  45. Slide 45: ML FRONTIER

    ML FRONTIER(tm) Designed to provide easy side branch access and good scaffolding Side Branch "Portal" Enables access into side branch Allows for "provisional T-stenting" Stent Pattern Modification of the clinically proven MULTI-LINK(r) design Novel Dual Balloon System Designed to deliver on one wire

  46. Slide 46: ML Frontier - Deployment Sequence

    ML FrontierTM - Deployment Sequence Currently under development at Guidant. Not available for sale

  47. Slide 47: Confidence in DES

    Confidence in DES

  48. Slide 48: Drug Eluting Stent Drives WW Vascular Market Growth

    1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Angioplasty 1455 1542 1496 1417 1393 1435 1398 1333 1286 1265 1255 1268 Bare Stent 94 507 873 1113 1717 1942 2021 1997 1972 1055 533 371 DES 0 0 0 0 0 0 0 0 108 2793 4555 5282 RT 0 0 0 0 0 0 7 80 115 105 83 60 EPD 0 0 0 0 0 0 0 24 78 152 19

  49. Slide 49: DES - US Market Size & Penetration for 2003

    DES - US Market Size & Penetration for 2003

  50. Slide 50: U.S. Reimbursement and Stent Costs

    U.S. Reimbursement and Stent Costs 1996 1997 2000 2001 2002 2003 Stent Cost / Procedure 2301 2353 1931 1628 1424 3875 Device Cost as % of Reimbursement 0.36 0.29 0.23 0.2 0.18 0.35 BDC Cost / Procedure 672 550 313 273 250 233 GW Cost / Procedure 186 171 129 125 119 116 GC Cost / Procedure 97 89 67 6

  51. Slide 51: DES Strategy

    DES Strategy

  52. Slide 52: Guidant DES Strategy

    Guidant DES Strategy: Guidant is committed to have the strongest, broadest offering in the drug eluting stent market* Sustainable leadership through: Full line of High Performance Platforms (WH, SVS, SVG, SBA) Different drug offerings Customize specific solutions for different lesions types Leverage

  53. Slide 53: Drug Eluting Stent Core Competencies

    Stent Tissue Drug Matrix Mechanical integrity Drug - carrier compatibility Loading capacity Release kinetics Mechanical scaffolding Vascular biology Tissue pharmacokinetics Preclinical models Vascular Compatibility Pharmacology Engineering Polymer Chemistry Vascular Biology Drug Eluting Stent Core C

  54. Slide 54: Interlock Technology

    Interlock Technology Description Paclitaxel interlocks with the specially prepared stent surface for durability Supporting data Utilizes paclitaxel's chemical composition and pharmacokinetics: Hydrophobic - remains on stent during delivery Lipophilic - diffuses into vessel wall on implantation

  55. Slide 55: Effects of MLD, Length, and Diabetes on Angiographic Restenosis

    Effects of MLD, Length, and Diabetes on Angiographic Restenosis - Why there is a need for specific solutions Guidant confidential. Not to be reproduced, distributed or excerpted.

  56. Slide 56: ACHIEVE Drug Eluting Coronary Stent System

    Guidant confidential. Not to be reproduced, distributed or excerpted. *Based on Cook's ASPECT & ELUTES trial data (performed on Supra G & V Flex Plus Stents), control vs. high dose. Caution: Investigational device. Limited by Federal (US) law to investigational use. ACHIEVE(tm) Drug Eluting Coronary

  57. Slide 57: ELUTES & ASPECT QCA Results

    ELUTES & ASPECT QCA Results Binary Restenosis Rate 0.0 1.0 2.0 3.0 4.0 0 10 30 Binary Restenosis Rate (%) ELUTES ASPECT Dose Density (µg/mm2) Source: Data from presentation by Dr. Gershlick at AHA Scientific Sessions 11/11/01 20

  58. Slide 58: Paclitaxel Program Progress

    Paclitaxel Program Progress DELIVER I completed ACHIEVE TM* CE mark Commercial release on hold pending legal clarity DELIVER II completed Caution: Investigational device (DES). Limited by Federal (US) law to investigational use only. Not available for sale.

  59. Slide 59: Clinical Trial Progress

    Clinical Trial Progress ACHIEVE TM* (paclitaxel eluting stent) DELIVER I Enrollment complete U.S. pivotal trial (n=1,043) 30-day MACE 0.8% at Euro PCR Follow up complete year-end PMA submission to follow shortly DELIVER I data release ACC '03 U.S. launch expected Q3 '03 (pending FDA approval) Cautio

  60. Slide 60: Deliver II Clinical Trial (OUS)

    Deliver II Clinical Trial (OUS) Prospective, multi-center, non-randomized clinical trial in high risk lesions 1500 patients at approximately 100 clinical sites in Europe and South America Key inclusion criteria: Diabetic patients Chronic total occlusions (single or double lesions occluded > 3 months

  61. Slide 61: Everolimus DES program update

    Everolimus DES program update Guidant and Novartis Novartis supplies drug and supporting data for regulatory filings Worldwide license agreement Novartis completed phase III human trials on Certican Everolimus in same family as Sirolimus Preclinical studies ongoing - dosing evaluations to be present

  62. Slide 62: The Next Big Thing

    The Next Big Thing

  63. Slide 63: The Human Vulnerable Plaque

    The Human Vulnerable Plaque GUIDANT

  64. Slide 64: Background: Stable vs. Vulnerable Lesions

    Thin capped fibroatheroma Eroded plaque, Lipid core minimal 60-70% 30-40% "VULNERABLE" PLAQUES Typically non-stenotic prior to event Unstable angina AMI SCD ACUTE CORONARY SYNDROMES Fibrous plaque, Slowly occlusive "STABLE" PLAQUES Stenotic Silent occlusion Stable angina Virmani et al, Arterioscler

  65. Slide 65: Vulnerable Plaque Summary

    Vulnerable Plaque Summary Stenting holds great promise as a therapy for VP New invasive diagnostics are needed to conduct therapy trials with stents Clinical trials are necessary to demonstrate VP treatment Future therapy optimization depends on diagnostic and trial data Guidant is positioned for le

  66. Slide 66: Massachusetts General Hospital (MGH) Study Summary

    Massachusetts General Hospital (MGH) Study Summary Optical Coherence Tomography (OCT) was successfully used to identify vulnerable lesion features in vivo in the current cath lab setting Guidant's study has observed lesion features in vivo known to be associated with AMI in autopsy Acute response to

  67. Slide 67: VI 2002 Highlights/ Forecast

    VI 2002 Highlights/ Forecast 1st Half International launch of Multi-Link ZETA WW BMW Universal launch DELIVER II registry started internationally DELIVER enrollment competed Mar 1st and 30 day data MACE presented at Euro PCR ELUTES - 1 year data presented at PCR Ruling in favor of GDT for MDT RX pat

  68. Slide 68: ES Vision

    ES Vision Revolutionizing endovascular therapies... Transforming lives Clinical solutions for the 50,000 miles of vessels outside the heart Easy to use products with superior clinical outcomes MD practice development for multiple specialties Programs to grow and develop markets Committed to quality

  69. Slide 69: Positioned for Leadership in Multiple Endovascular Therapies

    Endo AAA grafts & Pressure Sensor System Biliary stents & accessories Neurovascular solutions Drug Eluting Stents Carotid solutions Peripheral balloon dilatation caths & accessories Positioned for Leadership in Multiple Endovascular Therapies

  70. Slide 70: Large & Growing Markets

    Large & Growing Markets $2B WW market in 2005 Double-digit CAGR's: 2002-05 Peripheral 15% -- Carotid 45% Endo AAA 26% -- Neuro 14% > 15 million people affected by PVD, AAA & Stroke in U.S. PVD affects 5% of people >50 yrs AAA is 13th leading killer in U.S. Carotid artery disease causes 300,000 strok

  71. Slide 71: Treating More AAA Patients

    Treating More AAA Patients Treating ~35% of AAA Candidates >20fr delivery system 26mm diameter neck 13mm dia limbs 60° angulated necks Infrarenal fixation Shrink & control AAA 2-3 hour procedure 10 year durability testing Treating ~45% Aorto Uni Iliac Treating ~80% Limbs to 18mm dia Necks to 30mm di

  72. Slide 72: AAA Implant Segments & Monitoring Technology

    MODULAR Cook Zenith (1H/03) Litespeed (2006) Talent (1H/03) UNIBODY Ancure (10/99) Ancure Large Limbs/Necks (1H/03) Endologix Powerlink (1H/04) UNIBODY Trivascular (6/06) Endologix (1H/04) A/I Cook Zenith A/I (TBD) A/I Ancure A/I (4/02) PRESSURE SENSOR & SYSTEM Guidant (2/04) MODULAR AneuRx (10/99)

  73. Slide 73: Endo AAA: Market Drivers & Inhibitors

    Endo AAA: Market Drivers & Inhibitors Ease of use Treat more patients Larger diameter limbs 11?18mm Larger diameter necks 22?30mm Clinical data / durability Public and PCP awareness programs 2nd Generation devices Hospital & MD reimbursement FDA support of therapy 4?5 year follow-up data Competitive

  74. Slide 74: Endo AAA: U.S. $ Market Size

    Endo AAA: U.S. $ Market Size MDT GDT Gore Cook East 0.61 0.31 0.06 0.02 MDT GDT Gore Cook Others East 0.2 0.2 0.26 0.25 0.09 In 2005: Cook leads in suprarenal modular segment Gore, Medtronic, Guidant compete in infrarenal modular segment Guidant leads in infrarenal unibody and A/I 2002 $264M 2005* $

  75. Slide 75: U.S. Peripheral Interventional

    U.S. Peripheral Interventional 2002 $505M 2005* $816M Market drivers: patient awareness, MD training, DES platforms, reimbursement Market CAGR: 17% Sources: ES Peripheral market model; Harbaugh Associates, April 2002 * 2005 market share based on what MD's expect given current company familiarity and

  76. Slide 76: Peripheral Diagnostic & Interventional (USA)

    Guidant Cook Cordis Boston Bard Others East 65.6 199.7 303.6 383.8 25.2 75 2002 $1.1 B > $1 billion opportunity: Diagnostic ($548M*) + Interventional ($505M) Diagnostic: Cook ~30%; Guidant ES 0% Interventional: Cook ~7%; Guidant ES 13% IR's control >60% of volume Sources: ES Peripheral market model;

  77. Slide 77: Broader Interventional & ES + Cook Portfolio

    Broader Interventional & ES + Cook Portfolio ES Cook Stents SE ? ? BE ? BDC's 014 ? 018 ? 035 ? ? Guide Caths ? ? Diag Caths ? Guidewires 014 ? 018 ? ? 035 ? ? Introducers ? Vena Cava filter ? Infusion Caths ? Needles ? Dilators ? Adapters ? Endo AAA ? Europe DES Program ? ? Neuro ? ? ES adds 7 new

  78. Slide 78: Carotid Artery Stenting (CAS): Emerging New Therapy

    Carotid Artery Stenting (CAS): Emerging New Therapy 150,000 CEA's (carotid endarterectomy) per year CAS: 11,000 cases (7%) in 2002 and 43,500 (23%) in 2005 ARCHeR trial to complete enrollment in January ES results in Europe: 20% share in 4 Qtrs. Sources: Carotid Market model, SCVIR'02 survey, IMS He

  79. Slide 79: Drug Eluting Stents for Peripheral Vascular Disease

    Drug Eluting Stents for Peripheral Vascular Disease Everolimus being tested to reduce restenosis Paclitaxel (via Cook) presents potential additional opportunity Design includes Drug + Polymer + Stent + Delivery System

  80. Slide 80: DES Program with Everolimus

    DES Program with Everolimus Animal Data 30% stenosis expected at 3 months with bare stent Everolimus results at 28 days & 3 months: 14-15% stenosis Porcine model establishes safety at 3 months Bare Stent Control 28 days N=6 Everolimus 28 days N=6 Everolimus 3 months N=1

  81. Slide 81: New Product Launches - 2002 & 2003

    New Product Launches - 2002 & 2003 2002 Peripheral/Biliary Agiltrac .018 BDC Dynalink 80/100mm Agiltrac .035 BDC Dynalink SE 12/14 Carotid RX Acculink (CE) RX AccuNet (CE) Neuro NeuroLink (HDE) NeuroNet 2002 AAA Ancure Aorto-uniiliac Ancure Large Limbs (CE) AAA Deployment Pack 2003 Peripheral/Biliar

  82. Slide 82: Therapy Awareness & Market Development

    Therapy Awareness & Market Development Therapy awareness + reimbursement + MD training + clinical outcomes data patient family friends implanting MD primary care MD ? ?

Guidant — Merger or Acquisition (September 2002) on 6ix